IL4 and Alzheimer disease: In moderate-to-severe AD patients, the treatment with dupilumab, a human monoclonal antibody against IL-4Rα, rapidly improves the disease (56), suggesting the involvement of IL-4 and IL-13 in the pathogenesis of human AD.